These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 29140794)

  • 1. Targeted elimination of senescent Ras-transformed cells by suppression of MEK/ERK pathway.
    Kochetkova EY; Blinova GI; Bystrova OA; Martynova MG; Pospelov VA; Pospelova TV
    Aging (Albany NY); 2017 Nov; 9(11):2352-2375. PubMed ID: 29140794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of mTORC1 activity in senescent Ras-transformed cells neither restores autophagy nor abrogates apoptotic death caused by inhibition of MEK/ERK kinases.
    Kochetkova EY; Blinova GI; Bystrova OA; Martynova MG; Pospelov VA; Pospelova TV
    Aging (Albany NY); 2018 Nov; 10(11):3574-3589. PubMed ID: 30482887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of MEK/ERK pathway in the regulation of HDACI-induced senescence of transformed rat embryo fibroblasts].
    Kochetkova EIu; Bykova TV; Zubova SG; Pospelova TV
    Tsitologiia; 2014; 56(8):581-90. PubMed ID: 25697003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR kinase inhibitor pp242 causes mitophagy terminated by apoptotic cell death in E1A-Ras transformed cells.
    Gordeev SA; Bykova TV; Zubova SG; Bystrova OA; Martynova MG; Pospelov VA; Pospelova TV
    Oncotarget; 2015 Dec; 6(42):44905-26. PubMed ID: 26636543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coxsackievirus B3 induces autophagy in HeLa cells via the AMPK/MEK/ERK and Ras/Raf/MEK/ERK signaling pathways.
    Xin L; Ma X; Xiao Z; Yao H; Liu Z
    Infect Genet Evol; 2015 Dec; 36():46-54. PubMed ID: 26305625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status.
    Chao MW; Chang LH; Tu HJ; Chang CD; Lai MJ; Chen YY; Liou JP; Teng CM; Pan SL
    Clin Epigenetics; 2019 May; 11(1):85. PubMed ID: 31142371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the Ras-ERK pathway in pancreatic adenocarcinoma.
    Neuzillet C; Hammel P; Tijeras-Raballand A; Couvelard A; Raymond E
    Cancer Metastasis Rev; 2013 Jun; 32(1-2):147-62. PubMed ID: 23085856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin and Pemetrexed Have Distinctive Growth-inhibitory Effects in Monotherapy and Combination Therapy on
    Mohiuddin M; Kasahara K
    Cancer Genomics Proteomics; 2021; 18(4):579-590. PubMed ID: 34183390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing.
    Oh YT; Deng J; Yue P; Owonikoko TK; Khuri FR; Sun SY
    Oncogene; 2016 Jan; 35(4):459-67. PubMed ID: 25867065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The protein kinase MAP3K19 phosphorylates MAP2Ks and thereby activates ERK and JNK kinases and increases viability of KRAS-mutant lung cancer cells.
    Hoang VT; Nyswaner K; Torres-Ayuso P; Brognard J
    J Biol Chem; 2020 Jun; 295(25):8470-8479. PubMed ID: 32358059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unraveling the interplay between RAS/RAF/MEK/ERK signaling pathway and autophagy in cancer: From molecular mechanisms to targeted therapy.
    Huang Y; Zhen Y; Chen Y; Sui S; Zhang L
    Biochem Pharmacol; 2023 Nov; 217():115842. PubMed ID: 37802240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.
    McCubrey JA; Milella M; Tafuri A; Martelli AM; Lunghi P; Bonati A; Cervello M; Lee JT; Steelman LS
    Curr Opin Investig Drugs; 2008 Jun; 9(6):614-30. PubMed ID: 18516761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of MEK in lung cancer therapeutics.
    Heigener DF; Gandara DR; Reck M
    Lancet Respir Med; 2015 Apr; 3(4):319-27. PubMed ID: 25801412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
    Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
    EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
    Manov I; Pollak Y; Broneshter R; Iancu TC
    FEBS J; 2011 Sep; 278(18):3494-507. PubMed ID: 21790999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.